Cost of new drug development is key concern for life science as focus shifts to repurposing: WTW Survey

The survey also revealed that regulation and reputation risk have risen to the top of the life science agenda as companies feel pressure on a range of issues such as increasing regulatory activity post-Covid, U.S. drug price controls, rising data privacy concerns, ESG...